Alving, Kjell, Robert Anolik, Glenn Crater, Craig F. LaForce, and Kathy Rickard. “Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma.” Pulmonary Therapy, February 24, 2017. https://doi.org/10.1007/s41030-017-0032-8.

Anzueto, Antonio, Gary T. Ferguson, G Feldman, K Chinsky, A Seibert, Amanda Emmett, Katharine Knobil, Dianne O’Dell, Chris J. Kalberg, and Glenn Crater. “Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes.” J. COPD 6, no. 5 (October 2009): 320–29. https://doi.org/10.1080/15412550903140881.

Badesch, David B, Michael D McGoon, Robin J Barst, Victor F Tapson, Lewis J Rubin, Fredrick M Wigley, Kenneth M Kral, I Raphiou, and G Crater. “Longterm Survival Among Patients with Scleroderma-Associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol.” The Journal of Rheumatology 36, no. 10 (October 2009): 2244–49. http://www.jrheum.org/content/36/10/2244.abstract.

Barnes, Chris N., Donald A. Mahler, Jill A. Ohar, David A. Lombardi, and Glenn D. Crater. “Peak Inspiratory Flows: Defining Repeatability Limits and a Predictive Equation for Different Inhalers.” Chest 158, no. 4 (October 2020): 1413–19. https://doi.org/10.1016/j.chest.2020.03.072.

Bateman, Eric, Gregory Feldman , Sally Kilbride, Jean Brooks, Rashmi Mehta, Stephanie Harris, Claire Maden, and Glenn Crater. “Efficacy and Safety of the Long-Acting Muscarinic Antagonist GSK233705 Delivered Once Daily in Patients with COPD.” The Clinical Respiratory Journal 6, no. 4 (October 2012): 248–57. https://doi.org/10.1111/j.1752-699X.2011.00278.x.

Bleecker, Eugene R, Amanda Emmett, Glenn Crater, Katharine Knobil, and Christopher Kalberg. “Lung Function and Symptom Improvement with Fluticasone Propionate/Salmeterol and Ipratropium Bromide/Albuterol in COPD: Response by Beta-Agonist Reversibility.” Pulmonary Pharmacology & Therapeutics 21, no. 4 (August 2008): 682–88. https://doi.org/10.1016/j.pupt.2008.04.003.

Cahn, Anthony, Ruth Tal-Singer, Isabelle J. Pouliquen, Rashmi Mehta, Andrew Preece, Kelly Hardes, Glenn Crater, and Amanda Deans. “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies.” Clinical Drug Investigation 33, no. 7 (2013): 477–88. https://doi.org/10.1007/s40261-013-0088-7.

Celli, Bartolome, Glenn Crater, Sally Kilbride, Rashmi Mehta, Maggie Tabberer, Chris J. Kalberg, and Alison Church. “Once-Daily Umeclidinium/Vilanterol 125/25 Μg Therapy in COPD: A Randomized, Controlled Study.” CHEST Journal 145, no. 5 (May 1, 2014): 981. https://doi.org/10.1378/chest.13-1579.

Chatterjee, Arjun, Manan Shah, Anna O D’Souza, Benno Bechtel, Glenn Crater, and Anand A Dalal. “Observational Study on the Impact of Initiating Tiotropium Alone versus Tiotropium with Fluticasone Propionate/Salmeterol Combination Therapy on Outcomes and Costs in Chronic Obstructive Pulmonary Disease.” Respiratory Research 13 (February 2012): 15. https://doi.org/10.1186/1465-9921-13-15.

Crater, G D, M R Gregg, and G Holzwarth. “Mobility Surfaces for Field-Inversion Gel Electrophoresis of Linear DNA.” Electrophoresis 10, no. 5–6 (1989): 310–15. https://doi.org/10.1002/elps.1150100507.

Crater, Glenn D. “Levalbuterol vs Racemic Albuterol: Science or Drug Company Propaganda?” Chest 124, no. 3 (2003): 1175–76; author reply 1176-1178. http://www.ncbi.nlm.nih.gov/pubmed/12970056.

———. “Separating Chromosomal Sized DNA.” Journal of the Collegiate Academy of the North Carolina Academy of the Sciences 35 (1989): 1–8.

Crater, Glenn D., Karmon Johnson, Jonathan Ward, and Jan De Backer. “Lung Deposition of Inhaled Once-Daily Long-Acting Muscarinic Antagonists via Standard Jet Nebulizer or Dry Powder Inhaler, Measured Using Functional Respiratory Imaging, in Patients with Chronic Obstructive Pulmonary Disease.” Therapeutic Advances in Respiratory Disease 16 (2022): 175346662210775. https://doi.org/10.1177/17534666221077561.

Crater, Glenn, Kathy Rickard, and Neal Jain. “Successful Fractional Exhaled Nitric Oxide Measurements with NIOX VERO Using 6- and 10-s Exhalation Modes in Children with Asthma Aged 4–10 Years: A Randomized Study.” Pulmonary Therapy, 2017, 1–10. https://doi.org/10.1007/s41030-017-0028-4.

Dalal, Anand A, Manan B Shah, Anna O D’Souza, Amol D Dhamane, and Glenn D Crater. “Outcomes Associated with Timing of Maintenance Treatment for COPD Exacerbation.” The American Journal of Managed Care 18, no. 9 (September 2012): e338-345.

Dalal, Anand A, Manan B Shah, Anna O D’Souza, Orsolya E Lunacsek, Saurabh P Nagar, and Glenn D Crater. “Observational Study of the Outcomes and Costs of Initiating Maintenance Therapies in Patients with Moderate Exacerbations of COPD.” Respiratory Research 13, no. 1 (May 2012): 41. https://doi.org/10.1186/1465-9921-13-41.

Dalal, Anand A, Manan Shah, Anna O D’Souza, Sham Chaudhari, and Glenn Crater. “Clinical and Economic Outcomes for Patients Initiating Fluticasone Propionate/Salmeterol Combination Therapy (250/50 Mcg) versus Anticholinergics in a Comorbid COPD/Depression Population.” International Journal of Chronic Obstructive Pulmonary Disease 7 (January 2012): 11–19. https://doi.org/10.2147/COPD.S27846.

Dalal, Anand A, Manan Shah, Anna O D’Souza, and Glenn D Crater. “Rehospitalization Risks and Outcomes in COPD Patients Receiving Maintenance Pharmacotherapy.” Respiratory Medicine 106, no. 6 (June 2012): 829–37. https://doi.org/10.1016/j.rmed.2011.11.012.

Decramer, Marc, Antonio Anzueto, Edward Kerwin, Thomas Kaelin, Nathalie Richard, Glenn Crater, Maggie Tabberer, Stephanie Harris, and Alison Church. “Efficacy and Safety of Umeclidinium plus Vilanterol versus Tiotropium, Vilanterol, or Umeclidinium Monotherapies over 24 Weeks in Patients with Chronic Obstructive Pulmonary Disease: Results from Two Multicentre, Blinded, Randomised Controlled Trials.” The Lancet Respiratory Medicine, 2014. https://doi.org/10.1016/S2213-2600(14)70065-7.

Decramer, Marc, François Maltais, Gregory Feldman , Jean Brooks, Stephanie Harris, Rashmi Mehta, and Glenn Crater. “Bronchodilation of Umeclidinium, a New Long-Acting Muscarinic Antagonist, in COPD Patients.” Respiratory Physiology & Neurobiology 185, no. 2 (2013): 393–99. https://doi.org/10.1016/j.resp.2012.08.022.

Donohue, James F, Antonio Anzueto, Jean Brooks, Rashmi Mehta, Christopher Kalberg, and Glenn Crater. “A Randomized, Double-Blind Dose-Ranging Study of the Novel LAMA GSK573719 in Patients with COPD.” Respiratory Medicine 106, no. 7 (July 2012): 970–79. https://doi.org/10.1016/j.rmed.2012.03.012.

Donohue, James F., Gregory Feldman , Sanjay Sethi, Chris N. Barnes, Srikanth Pendyala, David Bourdet, and Glenn Crater. “Cardiovascular Safety of Revefenacin, a Once-Daily, Lung-Selective, Long-Acting Muscarinic Antagonist for Nebulized Therapy of Chronic Obstructive Pulmonary Disease: Evaluation in Phase 3 Clinical Trials.” Pulmonary Pharmacology & Therapeutics 57 (2019): 101808. https://doi.org/10.1016/j.pupt.2019.101808.

Donohue, James F., Edward Kerwin, Chris N. Barnes, Edmund J. Moran, Brett Haumann, and Glenn D. Crater. “Efficacy of Revefenacin, a Long-Acting Muscarinic Antagonist for Nebulized Therapy, in Patients with Markers of More Severe COPD: A Post Hoc Subgroup Analysis.” BMC Pulmonary Medicine 20, no. 1 (May 11, 2020): 134. https://doi.org/10.1186/s12890-020-1156-4.

Donohue, James F., Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran, and Glenn Crater. “Maintained Therapeutic Effect of Revefenacin over 52 Weeks in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD).” Respiratory Research 20, no. 1 (2019): 241. https://doi.org/10.1186/s12931-019-1187-7.

———. “Revefenacin, a Once-Daily, Lung-Selective, Long-Acting Muscarinic Antagonist for Nebulized Therapy: Safety and Tolerability Results of a 52-Week Phase 3 Trial in Moderate to Very Severe Chronic Obstructive Pulmonary Disease.” Respiratory Medicine 153 (July 2019): 38–43. https://doi.org/10.1016/j.rmed.2019.05.010.

Donohue, James, Nancy Herje, Glenn Crater, and Kathleen Rickard. “Characterization of Airway Inflammation in Patients with COPD Using Fractional Exhaled Nitric Oxide Levels: A Pilot Study.” International Journal of Chronic Obstructive Pulmonary Disease, 2014, 745. https://doi.org/10.2147/COPD.S44552.

Donohue, James, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran, and Glenn Crater. “Data on the Safety and Tolerability of Revefenacin, in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease.” Data in Brief 26 (October 2019): 104277. https://doi.org/10.1016/j.dib.2019.104277.

Dransfield, Mark T, William Bailey, Glenn Crater, Amanda Emmett, Dianne M O’Dell, and Barbara Yawn. “Disease Severity and Symptoms among Patients Receiving Monotherapy for COPD.” Primary Care Respiratory Journal 20, no. 1 (March 2011): 46–53. https://doi.org/10.4104/pcrj.2010.00059.

Dransfield, Mark T, John R Cockcroft, Raymond R Townsend, Harvey O Coxson, Sanjay S Sharma, David B Rubin, Amanda H Emmett, Michael J Cicale, Glenn D Crater, and Fernando J Martinez. “Effect of Fluticasone Propionate/Salmeterol on Arterial Stiffness in Patients with COPD.” Respiratory Medicine 105, no. 9 (September 2011): 1322–30. https://doi.org/10.1016/j.rmed.2011.05.016.

Feldman , Gregory, Robert R. Walker, Jean Brooks, Rashmi Mehta, and Glenn Crater. “28-Day Safety and Tolerability of Umeclidinium in Combination with Vilanterol in COPD: A Randomized Placebo-Controlled Trial.” Pulmonary Pharmacology & Therapeutics, August 2012. https://doi.org/10.1016/j.pupt.2012.08.007.

Ferguson, Gary T., Gregory Feldman, Krishna K. Pudi, Chris N. Barnes, Edmund J. Moran, Brett Haumann, Srikanth Pendyala, and Glenn Crater. “Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.” Chronic Obstructive Pulmonary Diseases (Miami, Fla.) 6, no. 2 (April 9, 2019): 154–65. https://doi.org/10.15326/jcopdf.6.2.2018.0152.

Hanania, Nicola A., Glenn D. Crater, Andrea N. Morris, Amanda H. Emmett, Dianne M. O’Dell, and Dennis E. Niewoehner. “Benefits of Adding Fluticasone Propionate/Salmeterol to Tiotropium in Moderate to Severe COPD.” Respiratory Medicine, January 2012. https://doi.org/10.1016/j.rmed.2011.09.002.

Heaney, Liam G, Ratko Djukanovic, Ashley Woodcock, Samantha Walker, John G Matthews, Ian D Pavord, Peter Bradding, et al. “Research in Progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).” Thorax 71, no. 2 (2016): 187–89. https://doi.org/10.1136/thoraxjnl-2015-207326.

Holzwarth, G, C B McKee, S Steiger, and G Crater. “Transient Orientation of Linear DNA Molecules during Pulsed-Field Gel Electrophoresis.” Nucleic Acids Research 15, no. 23 (1987): 10031–44. http://www.ncbi.nlm.nih.gov/pubmed/3697065.

Holzwarth, G, K J Platt, C B McKee, R W Whitcomb, and G D Crater. “The Acceleration of Linear DNA during Pulsed-Field Gel Electrophoresis.” Biopolymers 28, no. 6 (1989): 1043–58. https://doi.org/10.1002/bip.360280603.

Holzwarth, G, R W Whitcomb, K J Platt, G D Crater, and C B McKee. “Velocity of Linear DNA during Pulsed-Field Gel Electrophoresis.” In Electrophoresis of Large DNA Molecules: Theory and Applications, p.43-53. Current Communications in Cell and Molecular Biology. Cold Spring Harbor Laboratory Press, 1991. http://www.cshlpress.com/.

Kelleher, Dennis L, Rashmi S Mehta, Bernadette M Jean-Francois , Andy F Preece, James Blowers, Glenn D Crater, and Paul Thomas. “Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Umeclidinium and Vilanterol Alone and in Combination: A Randomized Crossover Trial.” PLoS ONE 7, no. 12 (December 17, 2012): e50716. https://doi.org/doi:10.1371/journal.pone.0050716.

Koser, Andras, Jan Westerman, Sanjay Sharma, Amanda Emmett, and Glenn D Crater. “Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease.” The Open Respiratory Medicine Journal 4 (October 2010): 86–91. https://doi.org/10.2174/1874306401004010086.

Mahler, Donald A., Jill A. Ohar, Chris N. Barnes, Edmund J. Moran, Srikanth Pendyala, and Glenn D. Crater. “Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate.” Chronic Obstructive Pulmonary Diseases (Miami, Fla.) 6, no. 4 (October 23, 2019). https://doi.org/10.15326/jcopdf.6.4.2019.0137.

Maltais, F., D. A. Mahler, V. Pepin, E. Nadreau, G. D. Crater, A. N. Morris, A. H. Emmett, and T. J. Ferro. “Effect of Fluticasone Propionate/Salmeterol plus Tiotropium versus Tiotropium on Walking Endurance in COPD.” European Respiratory Journal 42, no. 2 (August 1, 2013): 539–41. https://doi.org/10.1183/09031936.00074113.

Maltais, F., S. Singh, A. C. Donald, G. Crater, A. Church, A. H. Goh, and J. H. Riley. “Effects of a Combination of Umeclidinium/Vilanterol on Exercise Endurance in Patients with Chronic Obstructive Pulmonary Disease: Two Randomized, Double-Blind Clinical Trials.” Therapeutic Advances in Respiratory Disease 8, no. 6 (December 1, 2014): 169–81. https://doi.org/10.1177/1753465814559209.

Mehta, Rashmi, Kelleher, Andrew Preece, Hughes, and Crater. “Effect of Verapamil on Systemic Exposure and Safety of Umeclidinium and Vilanterol: A Randomized and Open-Label Study.” International Journal of Chronic Obstructive Pulmonary Disease, 2013, 159. https://doi.org/10.2147/COPD.S40859.

Mintz, Matthew, Barbara P Yawn, David M Mannino, James F Donohue, Nicola A. Hanania, Catherine A Grellet, Alicia W. Gilsenan, et al. “Prevalence of Airway Obstruction Assessed by Lung Function Questionnaire.” Mayo Clin Pro 86, no. 5 (May 2011): 375–81.

Ohar, Jill A, Glenn D Crater, Amanda Emmett, Thomas J Ferro, Andrea N Morris, Ibrahim Raphiou, Peruvemba S Sriram, and Mark T Dransfield. “Fluticasone Propionate/Salmeterol 250/50 Μg versus Salmeterol 50 Μg after Chronic Obstructive Pulmonary Disease Exacerbation.” Respiratory Research 15, no. 1 (2014): 105. https://doi.org/10.1186/s12931-014-0105-2.

Sabatelli, L, U Seppälä, J Sastre, and G Crater. “Cost-Effectiveness and Budget Impact of Routine Use of Fractional Exhaled Nitric Oxide Monitoring for the Management of Adult Asthma Patients in Spain.” Journal of Investigational Allergology and Clinical Immunology 27, no. 2 (March 1, 2017). https://doi.org/10.18176/jiaci.0103.

Sethi, Sanjay, James F. Donohue, Gary T. Ferguson, Chris N. Barnes, and Glenn D. Crater. “Efficacy and Safety of Revefenacin for Nebulization in Patients with Chronic Obstructive Pulmonary Disease Taking Concomitant ICS/LABA or LABA: Subgroup Analysis from Phase III Trials.” Therapeutic Advances in Respiratory Disease 14 (December 2020): 1753466620905278. https://doi.org/10.1177/1753466620905278.

Siler, Thomas M., Edmund J. Moran, Chris N. Barnes, and Glenn D. Crater. “Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day Study.” Chronic Obstructive Pulmonary Diseases (Miami, Fla.) 7, no. 2 (April 2020): 99–106. https://doi.org/10.15326/jcopdf.7.2.2019.0154.

Singh, Dave, Maxim Bogus, Valentyn Moskalenko, Robert Lord, Edmund J. Moran, Glenn D. Crater, David L. Bourdet, et al. “A Phase 2 Multiple Ascending Dose Study of the Inhaled Pan-JAK Inhibitor Nezulcitinib (TD-0903) in Severe COVID-19.” European Respiratory Journal 58, no. 4 (2021): 2100673. https://doi.org/10.1183/13993003.00673-2021.

Tacon, Claire, Hina Abbas, Shiyuan Zhang, Barbara Nicholls, Glenn Crater, and Zhen Su. “Trends in Canadian Respiratory Clinical Trials from 2001 to 2011.” Canadian Respiratory Journal: Journal of the Canadian Thoracic Society, December 23, 2013.

Tal-Singer, Ruth, Anthony Cahn, Rashmi Mehta, Andrew Preece, Glenn Crater, Dennis Kelleher, and Isabelle J. Pouliquen. “Initial Assessment of Single and Repeat Doses of Inhaled Umeclidinium in Patients with Chronic Obstructive Pulmonary Disease: Two Randomised Studies.” European Journal of Pharmacology 701, no. 1–3 (2013): 40–48. https://doi.org/10.1016/j.ejphar.2012.12.019.

Yawn, Barbara, David Mannino, Thomas Littlejohn, Gary Ruoff, Amanda Emmett, Ibrahim Raphiou, and Glenn Crater. “Prevalence of COPD among Symptomatic Patients in a Primary Care Setting.” Current Medical Research and Opinion 25, no. 11 (November 2009): 2671–77. https://doi.org/10.1185/03007990903241350.

Anzueto, Antonio, Gary T. Ferguson, G Feldman, A Seibert, K Chinsky, Amanda Emmett, Katharine Knobil, Dianne O’Dell, Christopher Kalberg, and Glenn Crater. “A Randomized, Double-Blind Trial Comparing the Effects of Fluticasone Propionate/Salmeterol 250/50 with Salmeterol on COPD Exacerbations.” In Am. J. Respir. Crit. Care Med. Toronto, Canada, 2008.

Celli, B., A. Emmett, G. Crater, and C. Kalberg. “Salmeterol/Fluticasone Propionate (SFC) Improves the Inspiratory to Total Lung Capacity Ratio (IC/TLC) and Exercise Endurance Time in Patients with COPD.” In European Respiratory Society 16th Annual Congress, 2–6, 2006.

Celli, Bartolome, Amanda Emmett, and Glenn Crater. “Fluticasone Propionate/Salmeterol (FSC) Improves the Inspiratory to Total Lung Capacity Ratio (IC/TLC) and Exercise Endurance Time in Patients with COPD.” In Am. J. Respir. Crit. Care Med. San Diego, CA, 2006.

Celli, Bartolome R, Amanda Emmett, and Glenn Crater. “The Inspriatory to Total Lung Capacity (IC/TLC) Correlates with Cycle Exercise Endurance Time in Patients with COPD.” In Am. J. Respir. Crit. Care Med. San Diego, CA, 2006.

Crater, G, M Panjehpour, and E Burdette. “Use of a Bolus Material in Conjunction with Ultrasound Hyperthermia for Heating Chest Wall Recurrences.” In North American Hyperthermia Group, 10th Annual Meeting, 10:39. New Orleans, LA, 1990.

Crater, Glenn D, Anand A Dalal, A Gilsenan, Lori McLeod, C Grellet, I Raphiou, and Barbara Yawn. “Prevalence of Chronic Obstruction Pulmonary Disease in Subjects with a History of Cigarette Smoking Assessed in a Primary Care Setting.” In Am. J. Respir. Crit. Care Med., 2010.

Crater, Glenn D, David M Mannino, T Littlejohn, G Ruoff, Amanda Emmett, Chris J. Kalberg, I Raphiou, and Barbara Yawn. “Disease Co-Morbidities in a Subject Population with a History of Cigarette Smoking and Symptoms of Chronic Bronchitis as Potential Precursors of COPD.” In Am. J. Respir. Crit. Care Med., Vol. 179, 2009.

Crater, Glenn D, Barbara Yawn, William Bailey, Mark T Dransfield, Amanda Emmett, and Dianne M O’Dell. “Prevalence of COPD, Disease Severity, and Symptoms in Subjects on Long-Acting Bronchodilator Monotherapy for COPD.” In Am. J. Respir. Crit. Care Med., 2010.

Crater, Glenn, Anand Dalal, and M Reed. “Undetected COPD in the US Adult Population.” In Am. J. Respir. Crit. Care Med. Toronto, Canada, 2008.

Crater, Glenn, David M Mannino, T Littlejohn, G Ruoff, Amanda Emmett, Christopher Kalberg, Ibrahim Raphiou, and Barbara Yawn. “Prevalence of COPD-Defined Airflow Obstruction in Undiagnosed Subjects with Symptoms of Chronic Bronchitis in Primary Care" ATS 2009.” In Am. J. Respir. Crit. Care Med., Vol. 179. San Diego, CA, 2009.

Crater, Glenn, Edmund Moran, Jonathan Ward, Dennis Belmans, and Cedric Van Holsbeke. “Lung Deposition of Two Bronchodilators in Subjects with (COPD) When Administered via Standard Jet Nebulizer or Handihaler® Using Functional Respiratory Imaging (FRI).” In Airway Pharmacology and Treatment, 637. European Respiratory Society, 2020. https://doi.org/10.1183/13993003.congress-2020.637.

Decramer, Marc, François Maltais, Gregory Feldman , Jean Brooks, L R Willits, Stephanie Harris, and Glenn Crater. “Dose-Related Efficacy of GSK573719, a New Long-Acting Muscarinic Receptor Antagonist (LAMA) Offering Sustained 24-Hour Bronchodilation, in COPD.” In Eur Respir J, Vol. 38: Suppl 55. Amsterdam, 2011.

Donohue, James, Antonio Anzueto, Jean Brooks, Rashmi Mehta, Chris Kalberg, and Glenn Crater. “Dose-Related Efficacy of GSK573719: A Long-Acting Muscarinic Receptor Antagonist (LAMA) With Sustained 24-Hour Activity in COPD.” Honolulu, HI, 2011.

Dransfield, Mark T., John R Cockcroft, Raymond R. Townsend, Harvey O. Coxson, Sanjay S. Sharma, David B. Rubin, Amanda Emmett, Michael J. Cicale, Glenn D Crater, and Fernando J Martinez. “Effect of Fluticasone Proprionate/Salmetrol (250/50) on Arterial Stiffness in Patients with COPD.” Denver, CO, 2011.

Dransfield, Mark T, John R Cockcroft, Raymond R. Townsend, Harvey O. Coxson, Sanjay S. Sharma, David B. Rubin, Amanda H. Emmett, Glenn D Crater, and Fernando J Martinez. “Severity of Arterial Stiffness Clincially Differentiates Moderate COPD Patients.” Denver, CO, 2011.

Erb, D, A Koser, Amanda Emmett, and Glenn D Crater. “Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler vs. Fluticasone Propionate/Salmeterol DISKUS in Subjects with COPD.” In Am. J. Respir. Crit. Care Med., 2010.

Feldman , Gregory, Robert R. Walker, Jean Brooks, Rashmi Mehta, and Glenn Crater. “Safety and Tolerability of the GSK573719/Vilanterol Combination in Patients with COPD.” In 108th International Conference of the American Thoracic Society. San Francisco, CA, 2012.

Ferguson, G., A. Anzueto, R. Fei, A. Emmett, G. Crater, K. Knobil, and C. Kalberg. “A Randomized, Double-Blind Trial Comparing the Effect of Fluticasone/Salmeterol 250/50 to Salmeterol on COPD Exacerbations in Patients with COPD.” In Chest, 132:530b, 2007.

Hanania, N. A, A. Anzueto, A. Emmett, and G. D Crater. “Deleterious Effects of Exacerbations on Lung Function and Health Status in COPD.” In Chest, 134:p21004, 2008.

Hanania, Nicola A, Antonio Anzueto, Amanda Emmett, and Glenn Crater. “Differences in Symptoms That Precede an Exacerbation That Influence Treatment Decisions.” In European Respiratory Society 18th Annual Congress. Berlin, Germany, 2008.

Hanania, Nicola A, Dennis E Niewoehner, Glenn D Crater, Amanda Emmett, Dianne M O’Dell, and Michael J Cicale. “Triple Therapy of Fluticasone Propionate/Salmeterol Combination 250/50 Mcg and Tiotropium Improves Lung Function Compared to Tiotropium Monotherapy.” In CHEST 2010. Vancouver, BC, 2010.

Kelleher, Dennis, Rashmi Mehta, B Jean-Francois, Andrew Preece, James Blowers, Glenn Crater, and P Thomas. “Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK573719 and Vilanterol When Administered Separately and in Combination to Healthy Adult Japanese Subjects.” In 108th International Conference of the American Thoracic Society. San Francisco, CA, 2012.

Kelleher, Dennis, Andrew Preece, Rashmi Mehta, A Donald, Kelly Hardes, Anthony Cahn, and Glenn Crater. “Phase II Study of Once-Daily GSK573719 Inhalation Powder, a New Long-Acting Muscarinic Antagonist, in Patients with Chronic Obstructive Pulmonary Disease (COPD).” In Eur Respir J, Vol. 38: Suppl. 55. Amsterdam, 2011.

Make, Barry, Amanda Emmett, G Crater, and Chris J. Kalberg. “Improvements in Exercise Endurance Time (EET) with Fluticasone Propionate/Salmeterol (FSC): Correlations with Spirometry and Plethysmography.” In Am. J. Respir. Crit. Care Med. San Diego, CA, 2006.

Maltais, François, Donald A. Mahler, Véronique Pepin, Eric Nadreau, Glenn Crater, Andrea N Morris, Amanda Emmett, and Tom Ferro. “Effect of Fluticasone-Salmeterol Combination + Tiotropium vs Tiotropium on Exercise Tolerance, the Cause of Exercise Limitation and Lung Volumes in COPD.” In 108th International Conference of the American Thoracic Society. San Francisco, CA, 2012.

Mehta, Rashmi, Kelly Hardes, Anthony Cahn, Amy Newlands, A Donald, Andrew Preece, Dennis Kelleher, and Glenn Crater. “Safety, Tolerability and Pharmacokinetics (PK) of Repeated Doses of GSK573719 Inhalation Powder, a New Long-Acting Muscarinic Antagonist, in Healthy Adults.” In Eur Respir J, Vol. 38: Suppl. 55. Amsterdam, 2011.

Mehta, Rashmi, Dennis Kelleher, S Hughes, Andrew Preece, and Glenn Crater. “Evaluation of the Effect of  Verapamil, an Inhibitor of P-Glycoprotein and CYP3A4, on Systemic Exposure and Safety Profile of GSK573719, a New Long-Acting Muscarinic Antagonist, and Vilanterol, an Inhaled Long-Acting Beta-2 Agonist in Healthy Subjects.” In 108th International Conference of the American Thoracic Society. San Francisco, CA, 2012.

Mehta, Rashmi, Amy Newlands, Dennis Kelleher, Andrew Preece, Anthony Cahn, and Glenn Crater. “Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single Doses of GSK573719 Inhalation Powder, a New Long-Acting Muscarinic Antagonist (LAMA), in Patients with COPD.” In Eur Respir J, Vol. 38: Suppl. 55. Amsterdam, 2011.

Miller, David, Glenn Crater, and B Althoff. “Characteristics of Patients at Risk for COPD Compared to Patients Diagnosed with COPD.” In Am. J. Respir. Crit. Care Med. San Diego, CA, 2009.

———. “Factors Associated with Exacerbations in US Patients with COPD.” In Am. J. Respir. Crit. Care Med., Vol. 179. San Diego, CA, 2009.

Miller, David, Glenn D Crater, M Reed, Kourtney Davis, and Anne Grimm. “Prevalence of Self-Reported COPD, Chronic Bronchitis, Emphysema and Smokers’ Cough in US.” In Am. J. Respir. Crit. Care Med., Vol. 177, 2008.

O’Donnell, D.E., F. Sciurba, B. Celli, D.A. Mahler, K. Webb, C. Kalberg, G. Crater, and K. Knobil. “Effect of Fluticasone Propionate/Salmeterol 250/50 on Lung Hyperinflation and Exercise Endurance in Patients with COPD.” In Chest, 128:178S, 2005.

Siler, Thomas M, Edmund J Moran, Chris N Barnes, and Glenn D Crater. “Tolerability of Revefenacin and Formoterol via Nebulization in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease: A Subgroup Analysis of a Phase 3 Trial,” n.d., 1.

Siler, T.M., G.T. Ferguson, D.A. Lombardi, and G.D. Crater. “Revefenacin Improves Lung Function Regardless of Baseline Symptom Status in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of Phase 3 Trials.” In B41. THERAPEUTIC INTERVENTION, QUALITY IMPROVEMENT, AND TREATMENT ADHERENCE IN OBSTRUCTIVE LUNG DISEASE, A3327–A3327. American Thoracic Society, 2020. https://doi.org/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3327.

Singh, David, Dennis E Niewoehner, Nicola A Hanania, Glenn D Crater, Andrea N Morris, Amanda H. Emmett, and Dianne M O’Dell. “Variability in Lung Function in Subjects Receiving Maintenance Therapy.” Denver, CO, 2011.

Yawn, B., D. Mannino, T. Littlejohn, G. Ruoff, A. Emmett, C. Kalberg, I. Raphiou, and G. D Crater. “Prevalence of COPD-Defined Airflow Obstruction in Undiagnosed Primary Care Subjects with Symptoms of Chronic Bronchitis.” In Chest, 134:p20001, 2008.

ZuWallack, R., C. Fogarty, G. Giessel, M. McClung, N. Locantore, I. Raphiou, S. Harris, and G. D Crater. “Effect of Fluticasone Propionate/Salmeterol Combination on Change in Bone Mineral Density in Subjects with COPD.” In Chest, 134:p104002, 2008.